Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I)

Представлены материалы Российского регистра больных артритом (ОРЕЛ). В регистр включено 3276 пациентов из 11 крупнейших научно-практических центров Российской Федерации, расположенных в Москве, Санкт-Петербурге, Новосибирске, Казани, Туле, Ярославле, Тюмени. Обсуждаются основные цели создания регистров, сопоставляются результаты анализа данных Российского регистра ОРЕЛ и регистров стран Европы и США. Полученные данные свидетельствуют о неоднородности информации о клинических, лабораторных и инструментальных параметрах в национальных регистрах ряда стран Европы и США. По базовым характеристикам Российский регистр ОРЕЛ выгодно отличается от ряда других регистров полнотой сбора данных, что позволяет составить общее представление о пациентах, страдающих ревматоидным артритом (РА), в России. В плане дальнейшего развития регистра ОРЕЛ необходимо сконцентрировать внимание на следующих основных направлениях: повышение качества заполнения документации; динамическое наблюдение за пациентами, получающими различные схемы терапии РА согласно рекомендациям Ассоциации ревматологов России по лечению больных РА; углубленное изучение коморбидности, в первую очередь депрессивных рас-
стройств; анализ нежелательных реакций, затрудняющих проведение терапии РА; активное использование модулей для самооценки пациентами своего состояния; развитие медсестринской помощи и др.

ревматоидный артрит, регистры, коморбидность

1. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под. ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Nasonov EL, Nasonova VA, editors. Moscow: GEOTAR-media; 2008. P. 290–331].

2. Gliklich RE, Dreyer NA, editors. Registries for Evaluating Patient Outcomes: A User's Guide. AHRQ Publication No. 07EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality; 2007. P. 36–8.

3. Dreyer NA, Garner S. Registers for robust evidence. JAMA. 2009;302:790–1. doi: 10.1001/jama.2009.1092

4. Сатыбалдыев АМ, Каратеев ДЕ. Международный опыт регистров больных ревматоидным артритом. Зарубежные регистры. Современная ревматология. 2014;8(1):83–4 [Satybaldyev AM, Karateev DE. International practice of rheumatoid arthritis registries. Foreign registries. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;(1):83–4 (In Russ.)]. doi: 10.14412/1996-7012-2014-1-83-84

5. Curis JR, Jain A, Askling J, et al. A comparison of patients characteristics and outcome in selected European and U.S Rheumatoid Arthritis registries. Semin Arthritis Rheum. 2010;40:2–14. doi: 10.1076/j.semarthritis. 2010.03.003

6. Radner H, Dixon W, Hyrich K, Askling J. Consistency and utility of data items across European rheumatoid arthritis clinical cohort and registers. Arthritis Care Res. 2015 Apr 17. doi:10.1002/acr.22602 [Epub ahead of print].

7. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. С. 549 [Nasonov EL, editor. Gennoinzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. P. 549].

8. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;67(2):280–309. doi: 10.1124/pr.114.009639

9. Burmester GR, Feist E, Dorner T. Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:77–88. doi: 10.1038/nrrheum.2013.168

10. Feldman M, Maini RN. Can we get closer to a cure for rheumatoid arthritis? Arthritis Rheum. 2015;67(9):2283–91. doi: 10.1002/art.39269

11. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. doi: 10.1136/ard.2009.123919

12. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. doi:10.1136/annrheumdis-2013-204573

13. Smolen JS, Breedvald FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015 May 12. doi:10.1036/annrheumdis-2015-32075242014 [Epub ahead of print].

14. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации«Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All- Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):477–94 (In Russ.)]. doi: 10.14412/1995-4484- 2014-477-494

15. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015 May;11(5):276–89. doi:10.1038/nrrheum.2015.8

16. Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепциямультиморбидности в ревматологической практике. Научно-практическая ревматология. 2014;52(4):362–5 [Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):362–5]. doi: 10.14412/1995-4484-2014-362-365

17. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124–34. doi: 10.7326/0003-4819-148-2-200801150-00192

18. Pincus T, Gibson KA, Castrrejon I. Update of methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Joint Dis. 2013;71(Suppl 1):S9–S19.

19. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological diseasemodifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68:1105–12. doi: 10.1136/ard.2008.099861

20. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26 (In Russ.)]. doi: 10.14412/1995- 4484-2014-8-26

21. Buch MH, Pavitt S, Parmar M, Emery P. Creative trial design in RA: optimizing patient outcomes. Nat Rev Rheumatol. 2013;9:183–94 doi: 10.1038/nrrheum.2013.5 22. De Witt EM, Brunner HI. The landscape of comparative effectiveness research in rheumatology 2014;1:57–62. doi: 10.1038/nrrheum.2013.140

22. Arora A, Mahajan A, Spurden D, et al. Long-term drug survival of TNF inhibitor therapy in RA patients: a systemic review of European National Registers. Int J Rheumatol. 2013;2013:764518. doi: 10.1155/2013/764518

23. Busquets N, Tomero E, Descalzo MA, et al, on behalf of the BIOBADASER 2.0 Study Group. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology. 2011;50:1999–2004. doi:10.1093/rheumatology/ker281

24. Tomsic M, Rotar Z. The frequency of tuberculosis chemoprophylaxis prior to TNF-α inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registry. Ann Rheum Dis. 2012;71:1909–11. doi: 10.1136/annrheumdis- 2012-201913

25. Dixon WE, Watson KD, Lunt M, Hyrich KL. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905–12. doi:10.1002/art.22809

26. Bal A, Ataman S, Bodur H, et al. Characteristics of patients with rheumatoid arthritis in Turkey: Results from the Turkish League Against Rheumatism Rheumatoid Arthritis Registry. Arch Rheumatol. 2015;30(0):i–viii. doi: 10.5606/ArchRheumatol.2015.4224

27. Vermeer M, Hillechiena H, Kuper H, et al. Treating to the target of remission in early rheumatoid arthritis is cost-effective:results of the DREAM registry. BMC Musculoskel Disord.2013;14:350. doi: 10.1186/1471-2474-14-350

28. Hertland ML. DANBIO – powerful research database and electronic patients record. Rheumatology. 2011;50:69–77. doi: 10.1093/rheumatology/keq309

29. Canhao H, Faustino A, Martis F, Fonseca JE. Rheumatic disease Portuguese Register Board Coordination PSor. Rheuma.pt – the rheumatic disease Portuguesr register. Acta Reumatol Port. 2011;36:45–56.

30. Uitz E, Fransen J, Langenegger T, et al, for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis. Clinical quality management in rheumatoid arthritis: putting theory into practice. Rheumatology. 2000;39:537–41. doi:10.1093/rheumatology/39.5.537

31. Stamm TA, Aletaha D, Pflugberi S, et al. The use of databases for quality assessment rheumatoid arthritis. Clin Exp Rheumatol. 2007;25(Suppl 47):82–5.

32. Kvein TK, Heiberg LE, Kaufmann C, et al. A Norvegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic disease. Clin Exp Rheumatol. 2005;23(Suppl 39):S188–94.

33. Saevarsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts. Arthritis Rheum. 2011;63:26–36. doi: 10.1002/art.27758

34. Van Aken J, van Bilsen JH, Allart CF, et al. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol. 2013;21(Suppl 31):S100–5.

35. Balogh E, Madruga Dias J, Orr C, et al. Comparison of remission criterias in tumor necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patients global health is a confounder. Arthritis Res Ther. 2013;15:R221. doi: 10.1186/ar4421

36. Neovius N, Simard JF, Sundströ m A, et al. for the ARTIS Study Group. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis. 2011;70(516–9. doi: 10.1136/ard.2010.130914

37. Dostal C, Pavelka K, Zvarova J, et al. Some principles of the development of a clinical database/national register of selected inflammatory rheumatic disease in the Czech Republic. Int J Med Inform. 2006;75:216–23. doi: 10.1016/j.ijmedinf. 2005.07.043

38. Rakieh C, Nam JL, Hunt L, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with nonspecific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015;74(9):1659–66. doi: 10.1136/annrheumdis-2014-205227

39. Wijbrandts CA, van Leuven DU, Boom HD, et al. Sustained changes in lipid profile and macrophage migration inhibitor factor levels after anti-tumor necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1316–21. doi: 10.1136/ard.2007.086728

40. Virkki LM, Valleale H, Takakuda Y, et al. Outcome of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from Finish Register of Biological Treatment (BOR-FIN). Clin Rheumatol. 2011;30:1447–54. doi:10.1007/s10067-011-1779-1

41. Zink A, Listing J, Strangfeld A, et al. Dose adjustment in patients treated with infliximab in routine rheumatologic care in Getmany. Results from the Biologics Register RABBIT. Z Rheumatol. 2006;65:441–6. doi: 10.1007/s00393-006-0033-8

42. Lapaduda G, Ferraccioli G, Ferry C, et al. GISEA: an Italian biological agents registry in rheumatology. Reumatismo. 2011;63:154–66. doi: 10.4081/reumatismo.2011.155

43. Codreanu C, Mogosan C, Ionescu R, et al. Biologic therapy in rheumatoid arthritis: results from the Romanian registry of rheumatic diseases one year after initiation. Farmacia. 2014;62(6):1089–96.

44. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis traditional factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69:1920–5. doi: 10.1136/ard2009.122226

45. Министерство здравоохранения и социального развития Российской Федерации. Об утверждении Порядка оказания медицинской помощи больным с ревматическими болезнями. Приказ от 16 апреля 2010 г. [Ministerstvo zdravookhraneniya i sotsial'nogo razvitiya Rossiiskoi Federatsii. Ob utverzhdenii Poryadka okazaniya meditsinskoi pomoshchi bol'nym s revmaticheskimi boleznyami. Prikaz ot 16 aprelya 2010 g. [The Ministry of Health and Social Development of the Russian Federation. On approval of the provision of medical care to patients with rheumatic diseases. Order from April 16, 2010]].

46. Насонов ЕЛ, Лукина ГВ, Сигидин ЯА. Комбинированная терапия ритуксимабом и лефлуномидом при ревматоидном артрите (предварительные результаты российского регистра АРБИТР). Научнo-практическая ревматология. 2011;(1):16–20 [Nasonov EL, Lukina GV, Sigidin YaA. Combination therapy for rheumatoid arthritis with rituximab and leflunomide (preliminary results of the russian ARBITR registry). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(1):16–20 (In Russ.)].

47. Chatzidionysiou KE, Lie E, Nasonov E, et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575–80. doi: 10.1136/ard.2010.148759

48. Chatzidionysiou KE, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in Rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374–7. doi: 1136/annrheumdis-2011-200003

49. Каратеев ДЕ, Насонов ЕЛ, Сатыбалдыев АМ. Общероссийский регистр пациентов с ревматоидным артритом: настоящее и будущее. Современная ревматология. 2014;(1):84–6 [Karateev DE, Nasonov EL, Satybaldyev AM. All-russian registry of rheumatoid arthritis patients: present and future. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;(1):84–6 (In Russ.)]. doi: 10.14412/1996-7012-2014-1-84-86

50. Каратеев ДЕ, Лучихина ЕЛ, Тюрина ЛН и др. Возможности ранней диагностики ревматоидного артрита в клинической практике на современном этапе (результаты наблюдений за московской когортой больных ранним артритом в рамках программы РАДИКАЛ). Терапевтический архив. 2008;(5):8–13 [Karateev DE, Luchikhina EL, Tyurina LN, et al. Possibilities of early diagnosis of rheumatoid arthritis in clinical practice at the present stage (the results of observations of the Moscow cohort of patients with early arthritis in the framework of the RADIKAL). Terapevticheskii arkhiv. 2008;(5):8–13 (In Russ.)].

51. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое Российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно- практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].

52. Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты лечения 130 больных в течение 12 месяцев. Научно-практическая ревматология. 2014;52(6):607–14 [Karateev DE, Luchikhina EL, Demidova NV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):607–14 (In Russ.)]. doi: 10.14412/1995-4484-2014-607-614

53. Пчелинцева АО, Панасюк ЕЮ, Рябицева ОФ и др. Эффективность этанерцепта у больных ревматоидным артритом (результаты российского многоцентрового исследования ЭТАЛОН). Научно-практическая ревматология. 2013;51(6):639–45 [Pchelintseva AO, Panasyuk EYu, Ryabitseva OF, et al. Efficacy of etanercept in patients with rheumatoid arthritis (results of the Russian multicenter ETALON study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):639–45 (In Russ.)]. doi: 10.14412/1995-4484-2013-639-45

54. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24. doi: 10.1002/art.1780310302

55. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81. doi: 10.1002/art.27584

56. Каратеев ДЕ, Олюнин ЮА. О классификации ревматоидного артрита. Научно-практическая ревматология. 2008;(1):5–16 [Karateev DE, Olyunin YuA. On the classification of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;(1):5–16 (In Russ.)].

57. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. 752 c. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatology. Clinical guidelines]. Moscow: GEOTARMedia; 2010. 752 p.].

58. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2011;365:2205–19. doi: 10.1056/NEJMra1004965

59. Cho JH, Feldman M. Heterogeneity of autoimmune diseases: pathophysiologic insight from genetics and implications for new therapy. Nat Med. 2015;21:730. doi: 10.1038/nm.3897

60. Schett G, Elewaut D, McInnes JB, et al. How cytokine network fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med. 2013;19:822–4. doi: 10.1038/nm.3260

61. Насонов ЕЛ. Ревматоидный артрит: проблемы и значение персонифицированной медицины. Терапевтический архив. 2012;(5):5–9 [Nasonov EL. Rheumatoid arthritis: the problem and the importance of personalized medicine. Terapevticheskii arkhiv. 2012;(5):5–9 (In Russ.)].

62. Iannaccone CK, Lee YC, Cui J, et al. Using genetic and clinical data to understand response to disease-modifying antirheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequental Study. Rheumatology. 2011;500:40–6. doi: 10.1093/rheumatology/keq263

63. Plant D, Thompson W, Lunt M, et al. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology. 2011;50:78–84. doi:10.1093/rheumatology/keq032

64. Available from: http://www.gks.ru/free_doc/new_site/perepis2010/croc/perepis_itogi1612.htm

65. Cutolo M, Kitas GD, van Riel PLCM. Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. Semin Arthritis Rheum. 2014;43:479–88. doi: 10.1016/j.semarthrit.2013.08.004

66. Radner H, Yoshida K, Solomon DH. Multimorbidity and rheumatic conditions – enhancing the concept of comorbidity. Nat Rev Rheumatol. 2014;10:252–6. doi: 10.1038/nrrheum.2013.212

67. Radber H, Yoshida K, Hmamouchi I, et al. Treatment patterns of multimorbid patients with rheumatoid arthritis: results from an International cross-sectional study. J Rheumatol. 2015;42:1099–104. doi: 10.3899/jrheumat.141534

68. Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidity are associated with poorer outcome in community patients with rheumatoid arthritis. Rheumatology. 2013;52:1809–17. doi:10.1093/rheumatology/ket224

69. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extraarticular manifestations in RA and their impact on outcome. Rheumatology. 2013;52:99–110. doi: 10.1093/rheumatology/kes262

70. Crepaldi G, Scire C.A, Carrara G, et al. Dissecting the impact of comorbidities on disease activity in rheumatoid arthritis: ancillary analysis from the COMORA Study. Ann Rheum Dis. 2014;73(Suppl 2):643. doi: 10.1136/annrheumdis-2014-eular.4388

71. Gerhold K, Richter A, Schneider M, et al. Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology 2015. doi: 10.1093/rheumatology/kev194

72. Richards J, Dowell SM, Quinones ME, Kerr GS. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. BMJ. 2015; 351:h3658. doi: 10.1136/bmj.h3658

73. Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015. doi: 10.3899/jrheumatol/141112

74. Pereira IA, da Mota LMH, Cruz BA, et al. 2012 Brazilian Society of Rheumatology consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52:474–95.

75. Hyrich K, Symmons D, Watson K, et al. BSRBR Control Centre Consortium on behalf of the British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national register. Ann Rheum Dis. 2006;65:895–8. doi: 10.1136/ard.2005.043158

76. Briggs AM, March L, Lassere M, et al. Baseline comorbidies in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian Rheumatology Association Database. Intern J Rheumatol. 2009; article ID861481

77. Forsblad-d'Elia H, Bengtsson K, Dehlin M, et al. Comparison between comorbid conditions in patients with rheumatoid arthritis with or without biological therapy: a registered-based cross-sectional study. Ann Rheum Dis. 2015;74:(Suppl 2):247. doi: 10.1136/annrheumdis-2015-eular.3184

78. Dougados M, Soubrier M, Antunes A. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73:62–8 doi:10.1136/annrheumdis-2013-204223

79. Sokka S, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491–6. doi:10.1136/ard.2006.069252

80. Лисицына ТА, Вельтищев ДЮ, Насонов ЕЛ. Стрессовые факторы и депрессивные расстройства при ревматических заболеваниях. Научно-практическая ревматология. 2013;51(2):98–103 [Lisitsyna TA , Veltishchev DYu, Nasonov EL. Stressors and depressive disorders in rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):98–103 (In Russ.)].

81. Cipriani P, Ruscitti P, Carubbi F, et al. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. Clin Ther. 2014;36:427–35. doi: 10.1016/j.clinthera.2014.01.014

82. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at dose ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51. doi:10.1136/annrheumdis-2014-205228

83. Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421–33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(4):421–33 (In Russ.)]. doi: 10.14412/1995-4484-2015-421-433

84. Curtis JR, Zhang J, Xie F, et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. 2014 Nov;66(11):1604–11. doi:10.1002/acr.22383

85. Alsaeedi S, Keystone EC. Oral or subcutaneous methotrexate for rheumatoid arthritis. Nat Rev Rheumatol. 2014 Oct;10(10):578–9. doi:10.1038/nrreum.2014.129

86. Muller RB, von Kempis J, Haile ER, Schiff MH. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-word data from the St.Gallen cohort. Semin Arthr Rheum. 2015. doi: 10.1016/j.semarthritis.2015.02.009

87. Strand V, Williams S, Miller PSJ, et al. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology Researchers of North America (CORRONA) database. Ann Rheum Dis. 2013;72(Suppl 3):71(P0064).

88. Agenova S, Steenberg HW, van Nies JAB, et al. Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms. Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2014-207080

89. Aga A-B, Lie E, Uhling T, et al. Time trends in disease activity, response and remission reates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000- 2010. Ann Rheum Dis. 2015;74:381–8. doi:0.1136/annrheumdis-1013-204020

90. Moura CS, Abrahamowicz M, Beachamp M-E, et al. Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther. 2015;17:197. doi: 10.1186/s13075-015- 0713-3

91. Wasko MC, Dasgupta A, Hubert H, et al. Propensity-adjustment association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334–42. doi: 10.1002/art.37723

92. Mikuls TR, Fay BT, Michaud K, et al. Associations of diseaseactivity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology.2011;50:101–9. doi: 10.1093/rheumatology/keq232

93. Pope JE, Hong P, Koehler BE. Prescribe trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologist. J Rheumatol. 2002;29:255–60.

94. Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum. 2005;53:740–7. doi: 10.1002/art.21467

95. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in UK over the past 20 years. Rheumatology (Oxford). 2011;50:1982–90. doi: 10.1093/rheumatology/ker017

96. Andre V, Le Goff B, Leux C, et al. Information on glucocorticoid therapy in the main studies of biological agents. Joint Bone Spain. 2011;78:478–83. doi: 10.1016/j.jbspin.2011.01.001

97. Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3):238–50 [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;53(3):238–250 (In Russ.)]. doi: 10.14412/1995-4484-2015-238-250

98. Emery O, van Vollenhoven RN, Ostergaard M, et al. Guidelines for initiation of anti-tumor necrosis therapy in rheumatoid arthritis: similarities and differences across Europe. Ann Rheum Dis. 2009;68:456–9. doi: 10.1136/ard.2008.100362

99. Putric P, Ramino S, Kvein TK, et al., Working Group «Equity in access to treatment of rheumatoid arthritis in Europe». Ann Rheum Dis. 2014;73(1):198–206. doi: 10.1136/annrheumdis- 2012-202603

100. Putric P, Ramino S, Kvein TK, et al., Working Group «Equity in access to treatment of rheumatoid arthritis in Europe». Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? Ann Rheum Dis. 2014;73(11):2010–21. doi:10.1136/annrheumdis-2013-203819